{
    "organizations": [],
    "uuid": "6803839f97d2c05f09e06a1c4830748d0f057bef",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biogen-and-ionis-expand-strategic/brief-biogen-and-ionis-expand-strategic-collaboration-to-develop-drug-candidates-for-a-broad-range-of-neurological-diseases-idUSFWN1RM0DU",
    "ord_in_thread": 0,
    "title": "BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 20 (Reuters) - Biogen Inc:\n* BIOGEN AND IONIS EXPAND STRATEGIC COLLABORATION TO DEVELOP DRUG CANDIDATES FOR A BROAD RANGE OF NEUROLOGICAL DISEASES\n* BIOGEN INC - BIOGEN WILL PAY IONIS $1 BILLION IN CASH, INCLUDING AN EQUITY INVESTMENT IN IONIS STOCK AND AN UPFRONT PAYMENT\n* BIOGEN INC - WILL HAVE OPTION TO LICENSE THERAPIES ARISING OUT OF COLLABORATION AND WILL BE RESPONSIBLE FOR THEIR DEVELOPMENT AND COMMERCIALIZATION\n* BIOGEN INC - $1 BILLION PAYMENT INCLUDES $625 MILLION TO BUY 11.5 MILLION SHARES OF IONIS COMMON STOCK AT $54.34 PER SHARE, $375 MILLION UPFRONT PAYMENT\n* BIOGEN INC - UNDER TERMS OF COLLABORATION CO MAY PAY MILESTONE PAYMENTS, LICENSE FEES AND ROYALTIES ON NET SALES\n* BIOGEN INC - IN COLLABORATION, IONIS WILL BE RESPONSIBLE FOR IDENTIFICATION OF ANTISENSE DRUG CANDIDATES BASED ON SELECTED TARGETS\n* BIOGEN - IN COLLABORATION BIOGEN WILL BE RESPONSIBLE FOR AND PAY FOR NON-CLINICAL STUDIES, CLINICAL DEVELOPMENT, MANUFACTURING, AND COMMERCIALIZATION\n* BIOGEN - CO, IONIS EXPANDED COLLABORATION THROUGH NEW 10-YEAR AGREEMENT TO DEVELOP NOVEL ANTISENSE DRUG CANDIDATES FOR RANGE OF NEUROLOGICAL DISEASES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-20T22:33:00.000+03:00",
    "crawled": "2018-04-21T18:07:25.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "biogen",
        "inc",
        "biogen",
        "ionis",
        "expand",
        "strategic",
        "collaboration",
        "develop",
        "drug",
        "candidate",
        "broad",
        "range",
        "neurological",
        "disease",
        "biogen",
        "inc",
        "biogen",
        "pay",
        "ionis",
        "billion",
        "cash",
        "including",
        "equity",
        "investment",
        "ionis",
        "stock",
        "upfront",
        "payment",
        "biogen",
        "inc",
        "option",
        "license",
        "therapy",
        "arising",
        "collaboration",
        "responsible",
        "development",
        "commercialization",
        "biogen",
        "inc",
        "billion",
        "payment",
        "includes",
        "million",
        "buy",
        "million",
        "share",
        "ionis",
        "common",
        "stock",
        "per",
        "share",
        "million",
        "upfront",
        "payment",
        "biogen",
        "inc",
        "term",
        "collaboration",
        "co",
        "may",
        "pay",
        "milestone",
        "payment",
        "license",
        "fee",
        "royalty",
        "net",
        "sale",
        "biogen",
        "inc",
        "collaboration",
        "ionis",
        "responsible",
        "identification",
        "antisense",
        "drug",
        "candidate",
        "based",
        "selected",
        "target",
        "biogen",
        "collaboration",
        "biogen",
        "responsible",
        "pay",
        "study",
        "clinical",
        "development",
        "manufacturing",
        "commercialization",
        "biogen",
        "co",
        "ionis",
        "expanded",
        "collaboration",
        "new",
        "agreement",
        "develop",
        "novel",
        "antisense",
        "drug",
        "candidate",
        "range",
        "neurological",
        "disease",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}